Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Intercept Pharmaceuticals...

    NASDAQ: ICPT · Real-Time Price · USD
    19.00
    0.04 (0.21%)
    At close: Nov 07, 2023, 9:00 PM

    Intercept Pharmaceuticals Statistics

    Share Statistics

    Intercept Pharmaceuticals has 41.83M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 41.83M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 584,432

    FTD / Avg. Volume

    n/a
    		 28.45%

    Short Selling Information

    The latest short interest is 10.14M, so 24.23% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 10.14M

    Short % of Shares Out

    n/a
    		 24.23%

    Short % of Float

    n/a
    		 25.18%

    Short Ratio (days to cover)

    n/a
    		 8.34

    Valuation Ratios

    The PE ratio is 3.63 and the forward PE ratio is null. Intercept Pharmaceuticals's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 3.63

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 1.46

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 4.49

    P/FCF Ratio

    n/a
    		 -15.3

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Intercept Pharmaceuticals has an Enterprise Value (EV) of 700.53M.

    EV / Sales

    n/a
    		 2.45

    EV / EBITDA

    n/a
    		 -11.35

    EV / EBIT

    n/a
    		 -26.16

    EV / FCF

    n/a
    		 -25.62

    Financial Position

    The company has a current ratio of 2.35, with a Debt / Equity ratio of 3.57.

    Current Ratio

    n/a
    		 2.35

    Quick Ratio

    n/a
    		 2.32

    Debt / Equity

    n/a
    		 3.57

    Debt / EBITDA

    n/a
    		 -5.39

    Debt / FCF

    n/a
    		 -12.16

    Interest Coverage

    n/a
    		 -3.19

    Financial Efficiency

    Return on Equity is 123.74% and Return on Invested Capital is 10.55%.

    Return on Equity

    n/a
    		 123.74%

    Return on Assets

    n/a
    		 20.8%

    Return on Invested Capital

    n/a
    		 10.55%

    Revenue Per Employee

    n/a
    		 $837,859.24

    Profits Per Employee

    n/a
    		 $337,753.67

    Employee Count

    n/a
    		 341

    Asset Turnover

    n/a
    		 0.52

    Inventory Turnover

    n/a
    		 0.15

    Taxes

    Income Tax

    n/a
    		 -290.03M

    Effective Tax Rate

    n/a
    		 165.87%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 0.88, so Intercept Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.88

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 16.63

    200-Day Moving Average

    n/a
    		 14.75

    Relative Strength Index (RSI)

    n/a
    		 75.79

    Average Volume (20 Days)

    n/a
    		 2,054,565

    Income Statement

    In the last 12 months, Intercept Pharmaceuticals had revenue of 285.71M and earned 115.17M in profits. Earnings per share was 3.41.

    Revenue

    n/a
    		 285.71M

    Gross Profit

    n/a
    		 284.73M

    Operating Income

    n/a
    		 -68.22M

    Net Income

    n/a
    		 115.17M

    EBITDA

    n/a
    		 -61.7M

    EBIT

    n/a
    		 -153.47M

    Earnings Per Share (EPS)

    n/a
    		 3.41
    Full Income Statement

    Balance Sheet

    The company has 50.52M in cash and 332.67M in debt, giving a net cash position of -282.16M.

    Cash & Cash Equivalents

    n/a
    		 50.52M

    Total Debt

    n/a
    		 332.67M

    Net Cash

    n/a
    		 -282.16M

    Retained Earnings

    n/a
    		 -2.14B

    Total Assets

    n/a
    		 393.16M

    Working Capital

    n/a
    		 292.6M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -26.78M and capital expenditures -568K, giving a free cash flow of -27.35M.

    Operating Cash Flow

    n/a
    		 -26.78M

    Capital Expenditures

    n/a
    		 -568K

    Free Cash Flow

    n/a
    		 -27.35M

    FCF Per Share

    n/a
    		 -0.81
    Full Cash Flow Statement

    Margins

    Gross margin is 99.66%, with operating and profit margins of -23.88% and 40.31%.

    Gross Margin

    n/a
    		 99.66%

    Operating Margin

    n/a
    		 -23.88%

    Pretax Margin

    n/a
    		 -61.2%

    Profit Margin

    n/a
    		 40.31%

    EBITDA Margin

    n/a
    		 -21.59%

    EBIT Margin

    n/a
    		 -23.88%

    FCF Margin

    n/a
    		 -9.57%

    Dividends & Yields

    ICPT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 27.53%

    FCF Yield

    n/a
    		 -6.54%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for ICPT.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -5.01

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist